<DOC>
	<DOCNO>NCT02514044</DOCNO>
	<brief_summary>The propose study aim evaluate safety efficacy combine dextroamphetamine ( Dexedrine ) transcranial direct current stimulation melodic intonation therapy treatment aphasia stroke . The target population patient chronic speech deficit due leave hemisphere non-hemorrhagic stroke . Findings propose project help design future large studies.The safety phase use cross-over , placebo control single-blinded design . 10 participant post stroke chronic non-fluent aphasia undergo two experiment . To study safety effect combine dextroamphetamine , tDCS MIT therapy study use parallel-groups , randomize , sham placebo control , double-blinded design 48 participant post stroke chronic non-fluent aphasia randomly assign receive either 1 ) dextroamphetamine therapy active stimulation , 2 ) placebo medication active stimulation , 3 ) dextroamphetamine therapy sham stimulation 4 ) placebo medication sham stimulation duration .</brief_summary>
	<brief_title>Dextroamphetamine tDCS Improve Fluency</brief_title>
	<detailed_description>The safety phase use cross-over , placebo control single-blinded design . 10 participant post stroke chronic non-fluent aphasia undergo two experiment . In experiment 1 , subject receive 10 mg dextroamphetamine , 1.5 mA anodal tDCS right inferior frontal gyrus ( right Broca 's area ) , melodic intonation therapy . The two experiment one time intervention separate 1 week washout subject come back experiment 2 , later side effect evaluate . In experiment 2 , subject receive placebo medication anodal tDCS right IFG ( Broca 's area ) melodic intonation therapy . During experiment , thirty minute stimulation , participant active drug experiment ( n=10 ) take 10 mg dextroamphetamine per oral -experiment 1- participant placebo drug experiment take placebo pill per oral -experiment 2- . During 20 minute stimulation phase , participant ( n=10 ) receive anodal tDCS ( 1.5 mA ) ipsilesional right inferior frontal gyrus ( Broca 's area ) . All participant simultaneously receive melodic intonation therapy duration hour 20 minute stimulation . To study safety effect combine dextroamphetamine , tDCS MIT therapy study use parallel-groups , randomize , sham placebo control , double-blinded design 48 participant post stroke chronic non-fluent aphasia randomly assign receive either 1 ) dextroamphetamine therapy active stimulation , 2 ) placebo medication active stimulation , 3 ) dextroamphetamine therapy sham stimulation 4 ) placebo medication sham stimulation duration . The subject previous step study ask participate step . Thirty minute stimulation participant active drug group , group 1 ( n=12 ) group 3 ( n=12 ) take dextroamphetamine 10 mg per oral participant placebo group , group 2 ( n=12 ) group 4 ( n=12 ) take placebo pill per oral . During 20 minute stimulation phase , participant active stimulation group , group 1 ( n=12 ) 2 ( n=12 ) receive anodal tDCS ( 1.5 mA ) right inferior frontal gyrus ( Broca 's area ) , participant sham control group , group 3 ( n=12 ) group 4 ( n=12 ) receive sham stimulation . All participant simultaneously receive melodic intonation therapy duration hour 20 minute stimulation . Treatment administer intensity 5 session per week 2 week .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<criteria>Age 18 Native English proficiency ; Nonfluent speech ; Premorbid right handedness ; Nonhemorrhagic leave hemispheric stroke least 6 month prior investigation . No contraindication MRI ( subject undergo MRI scan ) . Hypersensitivity idiosyncrasy dextroamphetamine sympathomimetic agent ; Pregnant try become pregnant ; Active alcohol abuse , illicit drug use drug abuse significant mental illness ; Subjects receive alpha adrenergic antagonist agonist ; Any history epilepsy ; Any condition would prevent subject give voluntary informed consent ; An implanted brain stimulator ; Aneurysm clip metal brain ; Enrolled plan enroll interventional trial study ; Scalp wound infection ; Previous stroke residual deficit ( TIAs reason exclusion ) ; A concurrent progressive neurologic disorder , acute coronary syndrome , severe heart disease ( NYHA Classification &gt; 3 ) , major medical condition ; Advanced atherosclerosis , Unstable cardiac dysrhythmia uncontrolled hypertension ( &gt; 160/100 mm Hg ) , untreated hyperthyroidism ; Diagnosis glaucoma During within 14 day follow administration monoamine oxidase inhibitor ; Subjects require palliative care ; Terminal medical condition AIDS cancer ; Subjects unable comprehend follow verbal command ; Based PI 's local physician 's assessment patient unable tolerate trial procedure due medical condition ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>